In order to better meet the demand and future needs of veterinarians for vaccination prevention on a global scale, Virbac is launching the construction of a new vaccine formulation and lyophilization building at its Carros site. The objective of this project, which will last three years, is to double the production capacity of vaccines for companion animals (dogs, cats, ferrets) against distemper, hepatitis, parvovirus, leptospirosis, rabies, typhus, coryza, and leukemia.

Representing an investment of 95 million euros, this new production unit will take over the activities of the Bio 4 site, also located in Carros, such as formulation, filling, and lyophilization. 

Securing the Supply Chain

This modern and ergonomic building will include new equipment, notably two freeze-dryers with automatic loading and unloading and isolators that will allow for better maintenance of asepsis.

In addition to increasing production capacity, this modernized production tool will make it possible to:

• secure the supply chain;
• develop the skills of our current and future employees drawn from the regional talent pool;
• meet the new regulatory requirements of Good Manufacturing Practices (GMP);
• align with the Group's CSR (Corporate Social Responsibility) policy by reducing waste and the energy footprint associated with this activity.

Construction work will be completed during 2027. Its commissioning is planned for the first half of 2029.

“The Bio 5 project marks a strong commitment from Virbac to making Carros a benchmark site for biology, equipped with the most advanced technologies, allowing for increased control and optimization of production costs. This new industrial tool will enable us to increase our volume targets to guarantee the competitiveness ambitions of Virbac vaccines and contribute to advancing animal health,” states Sébastien Scocci, Director of Strategic Industrial Projects in Biology at Carros.